- Page 1 and 2: PROGRAMME VIENNA, AUSTRIA APRIL 22-
- Page 3 and 4: VIENNA, AUSTRIA APRIL 22-26, 2015 O
- Page 5 and 6: A HISTORY OF INNOVATION A SUSTAINED
- Page 7 and 8: CONTENTS EASL Governing Board 8 Wel
- Page 9 and 10: EASL EDUCATIONAL COUNCILLORS EU POL
- Page 11 and 12: WELCOME MESSAGE Dear Colleague, Wel
- Page 13 and 14: LET US KNOW ON THE EASL INSPIRATION
- Page 15 and 16: WELCOME FROM THE HONORARY PRESIDENT
- Page 17 and 18: McPherson Stuart, United Kingdom Mo
- Page 19: Janssen Pharmaceutical Companies of
- Page 23 and 24: LIVER DISEASE IN RESOURCE-LIMITED S
- Page 25 and 26: WS = Joint Workshop cont. = continu
- Page 27 and 28: WEDNESDAY, APRIL 22, 2015 Strauss 1
- Page 29 and 30: THURSDAY, APRIL 23, 2015 Strauss 3
- Page 31 and 32: FRIDAY, APRIL 24, 2015 Early Mornin
- Page 33 and 34: SATURDAY, APRIL 25, 2015 Strauss 3
- Page 35 and 36: SUNDAY, APRIL 25, 2015 Stolz 2 Meta
- Page 37 and 38: SCIENTIFIC PROGRAMME WEDNESDAY APRI
- Page 39 and 40: Joint Workshop: EASL-ICA Strauss 1
- Page 41 and 42: Post-Graduate Course: Liver Transpl
- Page 43 and 44: Joint Workshop: EASL-Public Health
- Page 45 and 46: Joint Workshop: EASL-MSF-Prolifica-
- Page 47 and 48: Joint Workshop: EASL-Virtual Liver
- Page 49 and 50: Joint Workshop: EASL-International
- Page 51 and 52: Post Graduate Course - Metabolic Li
- Page 53 and 54: Basic Science Seminar - Liver Tumou
- Page 55 and 56: Nurses and Associates Forum Lehar 3
- Page 57 and 58: SCIENTIFIC PROGRAMME THURSDAY APRIL
- Page 59 and 60: Post Graduate Course - Metabolic Li
- Page 61 and 62: Basic Science Seminar - Liver Tumou
- Page 63 and 64: Fellowship and Registry Grant Prese
- Page 65 and 66: Parallel Session: Viral Hepatitis C
- Page 67 and 68: Parallel Session: General Viral Hep
- Page 69 and 70: Parallel Session: Non-invasive mark
- Page 71 and 72:
Parallel Session: Alcohol and DILI
- Page 73 and 74:
Parallel Session: Liver immunology
- Page 75 and 76:
SCIENTIFIC PROGRAMME FRIDAY APRIL 2
- Page 77 and 78:
Clinical Use of HBsAg quantificatio
- Page 79 and 80:
General Session 2 & Award Ceremony
- Page 81 and 82:
Grand Rounds: Liver transplantation
- Page 83 and 84:
Joint workshop: EASL-EFSUMB Lecture
- Page 85 and 86:
Translational Workshop - Liver mito
- Page 87 and 88:
Parallel Session: Viral Hepatitis C
- Page 89 and 90:
Parallel Session: Cirrhosis and Com
- Page 91 and 92:
Parallel Session: Fatty Liver Disea
- Page 93 and 94:
Parallel Session: Liver Tumours: Cl
- Page 95 and 96:
SCIENTIFIC PROGRAMME SATURDAY APRIL
- Page 97 and 98:
General Session 3 & Award Ceremony
- Page 99 and 100:
Parallel Session: EU and Public Hea
- Page 101 and 102:
Parallel Session: Liver Inflammatio
- Page 103 and 104:
Parallel Session: Liver Transplanta
- Page 105 and 106:
Joint Workshop: EASL-EFSUMB Lecture
- Page 107 and 108:
Clinical Symposium - Bacterial infe
- Page 109 and 110:
Joint Workshop: EASL - JSH Stolz 2
- Page 111 and 112:
SCIENTIFIC PROGRAMME SUNDAY APRIL 2
- Page 113 and 114:
Study design in gut microbiome asse
- Page 115 and 116:
30 Years of Journal of Hepatology:
- Page 117 and 118:
Clinical Symposium - Value-Based Me
- Page 119 and 120:
ePOSTERS THURSDAY, APRIL 23, 2015 F
- Page 121 and 122:
P0007 P0008 HEPATIC T-CELLS DERIVED
- Page 123 and 124:
YI P0020 YI P0021 YI P0022 ROLE OF
- Page 125 and 126:
P0033 P0034 P0035 PROSPECTIVE EVALU
- Page 127 and 128:
P0046 P0047 RESPONSE TO LOCO-ABLATI
- Page 129 and 130:
YI P0058 YI P0059 SOFOSBUVIR-BASED
- Page 131 and 132:
YI P0068 YI P0069 ALCOHOLIC ETIOLOG
- Page 133 and 134:
YI P0079 YI P0080 NUCLEOS(T)IDE ANA
- Page 135 and 136:
YI P1301 YI P1302 YI P1303 A NOVEL
- Page 137 and 138:
P0088 P0089 P0090 FERMENTED MILK CO
- Page 139 and 140:
TOP 10% YI P0102 YI P0103 YI P0104
- Page 141 and 142:
Cirrhosis and its Complications: Cl
- Page 143 and 144:
P0129 P0130 P0131 PORTAL HYPERTENSI
- Page 145 and 146:
P0140 P0141 P0142 FRAILTY ASSESSMEN
- Page 147 and 148:
P0151 P0152 COVERT HEPATIC ENCEPHAL
- Page 149 and 150:
P0162 P0163 P0164 CRITICAL FLICKER
- Page 151 and 152:
YI P0174 YI P0175 SOLUBLE CD163 (SC
- Page 153 and 154:
YI P0185 YI P0186 ACUTE-ON-CHRONIC
- Page 155 and 156:
Cirrhosis and its Complications: Bl
- Page 157 and 158:
YI P0210 YI P0211 COMBINED PARTIAL
- Page 159 and 160:
Liver Tumours: Experimental P0220 P
- Page 161 and 162:
P0232 P0233 P0234 REDUCED TRANSCRIP
- Page 163 and 164:
P0245 P0246 P0247 THE IL-6/SIL6R AN
- Page 165 and 166:
TOP 10% YI P0259 YI P0260 TRANSENDO
- Page 167 and 168:
YI P0271 YI P0272 YI P0273 EFFECTS
- Page 169 and 170:
YI P0283 YI P0284 YI P0285 ADENOSIN
- Page 171 and 172:
YI P0295 YI P0296 YI P0297 CD4+CD25
- Page 173 and 174:
YI P0309 YI P0310 GENE EXPRESSION P
- Page 175 and 176:
P0321 YI P0322 YI P0323 INCREASED A
- Page 177 and 178:
P0330 P0331 COST-EFFECTIVENESS ANAL
- Page 179 and 180:
P0341 P0342 P0343 DECREASING MORTAL
- Page 181 and 182:
P0355 P0356 THE EVALUATION OF AN AU
- Page 183 and 184:
YI P0367 YI P0368 YI P0369 SARCOPEN
- Page 185 and 186:
P0376 P0377 STRATIFICATION OF HEPAT
- Page 187 and 188:
YI P0387 YI P0388 YI P0389 IDENTIFI
- Page 189 and 190:
P0400 P0401 YI P0402 MICRORNA SIGNA
- Page 191 and 192:
YI P0414 YI P0415 YI P0416 CONSTITU
- Page 193 and 194:
P0426 P0427 INHIBITION OF MONOACYLG
- Page 195 and 196:
YI P0439 YI P0440 YI P0441 YI P0442
- Page 197 and 198:
Liver Immunology Including Viral He
- Page 199 and 200:
P0465 P0466 P0467 PERSISTENT INTRAH
- Page 201 and 202:
TOP 10% YI P0476 TOP 10% YI P0477 T
- Page 203 and 204:
YI P0488 YI P0489 DISSECTING THE CO
- Page 205 and 206:
YI P0501 YI P0502 YI P0503 REDUCED
- Page 207 and 208:
Non-Invasive Markers of Liver Fibro
- Page 209 and 210:
YI P0518 YI P0519 ARTERIAL PRESSURE
- Page 211 and 212:
Viral Hepatitis: Hepatitis B & D -
- Page 213 and 214:
P0543 P0544 P0545 COMPARATIVE EVALU
- Page 215 and 216:
YI P0556 YI P0557 YI P0558 ANTIVIRA
- Page 217 and 218:
Viral Hepatitis: Hepatitis A, B, D
- Page 219 and 220:
P0581 P0582 PREDICTION OF HBSAG SER
- Page 221 and 222:
P0592 P0593 P0594 A CROSS-SECTIONAL
- Page 223 and 224:
TOP 10% YI P0604 TOP 10% YI P0605 Y
- Page 225 and 226:
YI P0614 KEY HBSAG MUTATIONS SIGNIF
- Page 227 and 228:
YI P0625 YI P0626 A HYPER-GLYCOSYLA
- Page 229 and 230:
Viral Hepatitis: Hepatitis B & D -
- Page 231 and 232:
P0643 P0644 SERUM HBV RNA IS AN EAR
- Page 233 and 234:
P0654 P0655 LONG-TERM SUSTAINED SUP
- Page 235 and 236:
YI P0665 YI P0666 HBV VARIANTS PRES
- Page 237 and 238:
P0676 P0677 CLEARANCE OF PERSISTENT
- Page 239 and 240:
P0688 YI P0689 PRECLINICAL CHARACTE
- Page 241 and 242:
YI P0699 YI P0700 YI P0701 EPIGENET
- Page 243 and 244:
Viral Hepatitis: Hepatitis C - Clin
- Page 245 and 246:
P0720 P0721 IMPROVEMENT OF ADVANCED
- Page 247 and 248:
P0732 P0733 P0734 IMPACT OF OLD SCH
- Page 249 and 250:
P0745 P0746 EQ-5D UTILITY INDEX IN
- Page 251 and 252:
YI P0759 YI P0760 YI P0761 HEPATITI
- Page 253 and 254:
P0770 P0771 EFFECT OF HEPATITIS C A
- Page 255 and 256:
P0781 P0782 HIGH SVR RATES DESPITE
- Page 257 and 258:
P0789 P0790 EFFECTIVENESS, SAFETY A
- Page 259 and 260:
P0800 P0801 P0802 EFFECTIVENESS AND
- Page 261 and 262:
P0810 P0811 SOFOSBUVIR AND DACLATAS
- Page 263 and 264:
P0821 P0822 ARE EXTENDED DURATIONS
- Page 265 and 266:
P0834 P0835 SIGNIFICANT DRUG-DRUG I
- Page 267 and 268:
P0846 P0847 EVALUATION OF ADHERENCE
- Page 269 and 270:
P0857 P0858 98% SVR12 IN KOREAN AND
- Page 271 and 272:
P0869 P0870 EARLY VERSUS DELAYED US
- Page 273 and 274:
YI P0879 YI P0880 EXAMINING THE CLI
- Page 275 and 276:
Viral Hepatitis: Hepatitis C - Clin
- Page 277 and 278:
P0899 P0900 PRECLINICAL PROFILE OF
- Page 279 and 280:
P0910 YI P0911 NO EVIDENCE OF PHARM
- Page 281 and 282:
Fatty Liver Disease: Experimental P
- Page 283 and 284:
P0932 P0933 P0934 TREATMENT WITH NG
- Page 285 and 286:
YI P0944 YI P0945 YI P0946 MODULATI
- Page 287 and 288:
YI P0957 YI P0958 YI P0959 VITAMIN
- Page 289 and 290:
YI P0970 YI P0971 FAT-LADDEN MACROP
- Page 291 and 292:
Fatty Liver Disease: Clinical P0978
- Page 293 and 294:
P0990 P0991 P0992 NON-ALCOHOLIC STE
- Page 295 and 296:
P1002 P1003 THE HISTOLOGICAL SEVERI
- Page 297 and 298:
P1016 P1017 P1018 FACTORS ASSOCIATE
- Page 299 and 300:
P1028 P1029 P1030 IMPAIRED AEROBIC
- Page 301 and 302:
P1040 TOP 10% YI P1041 SHORT-TERM L
- Page 303 and 304:
YI P1050 YI P1051 ASSOCIATION OF FA
- Page 305 and 306:
YI P1061 YI P1062 YI P1063 THE MACR
- Page 307 and 308:
YI P1074 YI P1075 YI P1076 YI P1077
- Page 309 and 310:
P1089 P1091 P1092 CELLULAR SENESCEN
- Page 311 and 312:
P1103 P1104 P1105 PORTAL HYPERTENSI
- Page 313 and 314:
YI P1117 YI P1118 YI P1119 HISTOLOG
- Page 315 and 316:
YI P1132 YI P1133 YI P1134 REGULATI
- Page 317 and 318:
P1143 P1144 P1145 THYROID HORMONE R
- Page 319 and 320:
P1154 P1155 P1156 P1158 PRE-TREATME
- Page 321 and 322:
P1169 P1170 OUTCOME INDICATORS IN P
- Page 323 and 324:
YI P1180 YI P1181 IDENTIFICATION OF
- Page 325 and 326:
YI P1189 YI P1190 DECREASED SERUM T
- Page 327 and 328:
YI P1200 YI P1201 THE EFFECT OF AZA
- Page 329 and 330:
Genetic and Pediatric Liver Disease
- Page 331 and 332:
P1224 P1225 P1226 NEXT-GENERATION S
- Page 333 and 334:
YI P1238 YI P1239 YI P1240 INTERMED
- Page 335 and 336:
P1249 P1250 ALCOHOLIC LIVER DISEASE
- Page 337 and 338:
P1262 P1263 P1264 AN ACCURATE SCORE
- Page 339 and 340:
P1273 P1274 ACUTE PORTAL VEIN THROM
- Page 341 and 342:
YI P1288 BUDD CHIARI SYNDROM (BCS)
- Page 343 and 344:
P1313 P1314 WTX101-201: PHASE 2 STU
- Page 345 and 346:
P1323 YI P1324 YI P1325 A STUDY TO
- Page 347 and 348:
P1334 A MULTICENTRE, RANDOMISED, OP
- Page 349 and 350:
YI P1344 P1345 DETERMINING THE HEPA
- Page 351 and 352:
LATE BREAKER ePOSTERS
- Page 353 and 354:
LP05 LP06 DACLATASVIR PLUS SOFOSBUV
- Page 355 and 356:
LP14 LP15 A PHASE 3, RANDOMISED, OP
- Page 357 and 358:
LP24 LP25 SAFETY, EFFICACY AND IMPA
- Page 359 and 360:
LP34 LP35 EX VIVO LIVER RESECTION A
- Page 361 and 362:
LP44 LP45 PHAGOCYTOSIS: HOW THE BEG
- Page 364 and 365:
EVERYTHING YOU NEED FOR THE INTERNA
- Page 366 and 367:
TECHNICAL INFORMATION TECHNICAL INF
- Page 368 and 369:
EVENTS 2015 LIVER DISEASE IN RESOUR
- Page 370 and 371:
GENERAL INFORMATION GENERAL INFORMA
- Page 372 and 373:
GENERAL INFORMATION SPEAKERS' READY
- Page 374 and 375:
EVENTS 2016 T-CELL RESPONSES IN VIR
- Page 376 and 377:
SPONSORS’ SYMPOSIA WEDNESDAY, APR
- Page 378 and 379:
SPONSORS’ SYMPOSIA THURSDAY, APRI
- Page 380 and 381:
SPONSORS’ SYMPOSIA THURSDAY, APRI
- Page 382 and 383:
SPONSORS’ SYMPOSIA FRIDAY, APRIL
- Page 384 and 385:
SPONSORS’ SYMPOSIA SATURDAY, APRI
- Page 386 and 387:
VENUE FLOOR PLAN INDUSTRY INFORMATI
- Page 388 and 389:
EXHIBITORS LIST INDUSTRY INFORMATIO
- Page 390 and 391:
COMPANY PROFILES AbbVie 230 1 North
- Page 392 and 393:
Bristol-Myers Squibb 260 206, Provi
- Page 394 and 395:
Fresenius Medical Care 1, Else-Kroe
- Page 396 and 397:
IC-HEP - The International Coalitio
- Page 398 and 399:
Merz Pharmaceuticals GmbH 100, Ecke
- Page 400 and 401:
PhoenixBio 1-3-4, Kagamiyama 739004
- Page 402 and 403:
Steinhäuser Verlag 410 E SuperSoni
- Page 404 and 405:
Wisepress Bookshop 25 High Path Lon
- Page 406 and 407:
Cochrane Hepato-Biliary Rigshospita
- Page 408 and 409:
University of Liverpool 70 Pembroke
- Page 410 and 411:
NOTES 410 The International Liver C
- Page 412 and 413:
NOTES 412 The International Liver C
- Page 416 and 417:
OLYSIO ® - At the Core of HCV Cure
- Page 418:
Visit BOOTH 230 ALL NEW, ALL-ORAL,
Change language